Equity Profile

KOD

Kodiak Sciences Inc.

Health CareBiotechnology$2.5B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing treatments for eye diseases....

Key Metrics to Watch

EPS

Earnings per share is a critical indicator of the company's profitability and financial health.

$-0.92

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

KOD Q2-2026 Earnings Preview

Context

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing treatments for eye diseases. Operating in the health care sector, it aims to address significant unmet medical needs, particularly in retinal diseases, which could impact millions of patients globally.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

-0.51%

Last Quarter Recap

In Q1 2026, Kodiak reported an EPS of $-0.94, slightly missing analyst expectations. The stock reacted negatively, dropping 4.82% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Kodiak to report a loss this quarter, with a consensus EPS of $-0.92. There is uncertainty about revenue generation, as no revenue is expected.

Bull Case

If Kodiak can surprise the market with better-than-expected results or positive developments in its pipeline, it could lead to a significant stock rebound.

Bear Case

Conversely, if the company fails to meet EPS expectations or reveals setbacks in its drug development, it could further erode investor confidence.

Key Metrics to Watch

EPS

$-0.92

Earnings per share is a critical indicator of the company's profitability and financial health.

Revenue

$0M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Kodiak's EPS come in better than the consensus estimate of $-0.92?

A better-than-expected EPS could signal improved operational efficiency or cost management, which would be crucial for investor confidence.

Is there any update on the progress of Kodiak's drug pipeline?

Investors will closely watch for any news regarding the development of their treatments, as this could significantly impact future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Kodiak to surprise on EPS due to recent operational improvements that have not been fully reflected in analyst models.

Supporting Evidence

Kodiak has historically shown the ability to rebound after misses, as seen in Q4 2025.

The options market is pricing in a larger move than has been realized historically, suggesting potential for a surprise.

Recent developments in drug trials may not be fully accounted for in current estimates.

Key Risk

If Kodiak reports an EPS better than $-0.80, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Kodiak can turn around its performance after a series of misses, and the upcoming earnings report will be critical.

Bull Confirmed If

An EPS of $-0.80 or better would suggest improved financial performance and could validate the bull case.

Bear Confirmed If

An EPS worse than $-1.04 would reinforce concerns about the company's financial health and future prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±39.09%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating high volatility expectations around the earnings report.

Options are pricing ±39.1% while KOD has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

60.4%

Calls (22K)P/C Ratio: 0.43Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.7%, with a raw directional average of -1.4% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kodiak beats EPS expectations, history suggests the stock could rise by around 4.53%, confirming a positive turnaround narrative.

In-Line / Cautious

If results come in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 0.11% based on historical patterns, indicating continued investor skepticism.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any new trial results.
2Management's commentary on cost management and operational efficiency.
3Any insights into future revenue generation plans.
4Responses to analyst questions regarding competitive positioning.
5Guidance on upcoming milestones and expected timelines.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing treatments for eye diseases....

Key Metrics to Watch

EPS

Earnings per share is a critical indicator of the company's profitability and financial health.

$-0.92

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

KOD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

-0.51%

Last Quarter Recap

In Q1 2026, Kodiak reported an EPS of $-0.94, slightly missing analyst expectations. The stock reacted negatively, dropping 4.82% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Kodiak to report a loss this quarter, with a consensus EPS of $-0.92. There is uncertainty about revenue generation, as no revenue is expected.

Bull Case

If Kodiak can surprise the market with better-than-expected results or positive developments in its pipeline, it could lead to a significant stock rebound.

Bear Case

Conversely, if the company fails to meet EPS expectations or reveals setbacks in its drug development, it could further erode investor confidence.

Key Metrics to Watch

EPS

$-0.92

Earnings per share is a critical indicator of the company's profitability and financial health.

Revenue

$0M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Kodiak's EPS come in better than the consensus estimate of $-0.92?

A better-than-expected EPS could signal improved operational efficiency or cost management, which would be crucial for investor confidence.

Is there any update on the progress of Kodiak's drug pipeline?

Investors will closely watch for any news regarding the development of their treatments, as this could significantly impact future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Kodiak to surprise on EPS due to recent operational improvements that have not been fully reflected in analyst models.

Supporting Evidence

Kodiak has historically shown the ability to rebound after misses, as seen in Q4 2025.

The options market is pricing in a larger move than has been realized historically, suggesting potential for a surprise.

Recent developments in drug trials may not be fully accounted for in current estimates.

Key Risk

If Kodiak reports an EPS better than $-0.80, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Kodiak can turn around its performance after a series of misses, and the upcoming earnings report will be critical.

Bull Confirmed If

An EPS of $-0.80 or better would suggest improved financial performance and could validate the bull case.

Bear Confirmed If

An EPS worse than $-1.04 would reinforce concerns about the company's financial health and future prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±39.09%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating high volatility expectations around the earnings report.

Options are pricing ±39.1% while KOD has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

60.4%

Calls (22K)P/C Ratio: 0.43Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 14 of 29 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kodiak beats EPS expectations, history suggests the stock could rise by around 4.53%, confirming a positive turnaround narrative.

In-Line / Cautious

If results come in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 0.11% based on historical patterns, indicating continued investor skepticism.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any new trial results.
2Management's commentary on cost management and operational efficiency.
3Any insights into future revenue generation plans.
4Responses to analyst questions regarding competitive positioning.
5Guidance on upcoming milestones and expected timelines.